Advertisement CytRx begins operations at new discovery laboratory in Germany - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

CytRx begins operations at new discovery laboratory in Germany

CytRx, a US-based biopharmaceutical research and development firm, has started operations at its new discovery laboratory in Freiburg, Germany.

The new laboratory will be used to carry out discovery and research to develop drug candidates that use new linker technologies that couple chemotherapeutic agents and proteins either inside the body or externally, and then concentrate drug in tumors.

The discovery team, led by Drug Discovery vice president and inventor of aldoxorubicin Felix Kratz, and Drug Discovery senior director Andre Warnecke, will work to expand the company’s new albumin-binding anti-cancer drug pipeline.

CytRx president and chief executive officer Steven Kriegsman said under the leadership of Dr Kratz, an internationally recognized expert in conjugation chemistry, the company’s new discovery lab is now fully operational with multiple projects already started.

"Adding innovative product candidates to our future oncology pipeline is an important goal for CytRx and the work being done at our Freiburg lab is expected to yield a first clinical candidate by the second half of 2015," Kriegsman said.

"Bringing these research and development capabilities in-house allows us to control our pipeline, and rapidly move novel product candidates from bench to bedside."